NCT05582187View on ClinicalTrials.gov

A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Hepatic Impairment
Interventions
DRUG

Fosmanogepix

a single dose of fosmanogepix administered by mouth under fasted conditions

Trial Locations (2)

33603

RECRUITING

Genesis Clinical Research, LLC, Tampa

92337

RECRUITING

Inland Empire Liver Foundation, Rialto

Sponsors
All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Basilea Pharmaceutica

INDUSTRY

NCT05582187 - A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function. | Biotech Hunter | Biotech Hunter